SolaranRx, Inc. is developing a new class of precision medicine: therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics-often referred to as theranostics-constitutes a new level of precision medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patients' quality of life, giving new options to clinicians and hope to patients.
